Informed cytology for triaging HPV-positive women: Substudy nested in the NTCC randomized controlled trial

Journal of the National Cancer Institute

Volumn 107, Issue 2, 2015, Pages

  Bergeron, Christine ^a,b,c   Giorgi Rossi, Paolo ^k   Cas, Frederic ^a,b,c   Schiboni, Maria Luisa ^d   Ghiringhello, Bruno ^e   Palma, Paolo Dalla ^f   Minucci, Daria ^g   Rosso, Stefano ^e   Zorzi, Manuel ^h   Naldoni, Carlo ⁱ   Segnan, Nereo ^e   Confortini, Massimo ^j   Ronco, Guglielmo ^e  

^a LABORATOIRE CERBA   (France)

^b PATHOLOGY UNIT   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d SGiovanni Hospital Agency   (Italy)

^e CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^f SANTA CHIARA HOSPITAL   (Italy)

^g UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^h VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁱ Regione Emilia Romagna   (Italy)

^j Institute for Study and Cancer Prevention ISPO   (Italy)

^k University Hospital Città della Salute e della Scienza di Torino ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX DYSPLASIA; VAGINA SMEAR; VIROLOGY;

ADULT; ALPHAPAPILLOMAVIRUS; ATYPICAL SQUAMOUS CELLS OF THE CERVIX; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84925958095     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju423     Document Type: Article

References (26)

1. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88-F99.
2. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385-1394.
3. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: followup of four European randomised controlled trials. Lancet. 2014;383(9916):524-532.
4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
5. Baussano I, Ronco G, Segnan N, French K, Vineis P, Garnett GP. HPV-16 infection and cervical cancer: Modelling the influence of duration of infection and precancerous lesions. Epidemics. 2010;2(1):21-28.
6. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589-1597.
7. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672-682.
8. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial Lancet Oncol. 2012;13(1):78-88.
9. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249-257.
10. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human Papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst. 2006;98(11):765-774.
11. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006;7(7):547-555.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at Recruitment from a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone to Conventional Cytology as the Primary Cervical Cancer Screening Test. J Natl Cancer Inst. 2008;100(7):492-501.
13. Carozzi F, Confortini M, Dalla Palma P, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008;9(10):937-945.
14. Dalla Palma P, Giorgi Rossi P, Collina G, et al. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicentre randomized study. Am J Clin Pathol. 2009;132(1):125-132.
15. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Statistical Science. 1992;7(4):457-511.
16. Spiegelhalter DJ, Thomas A, Best NG. WinBUGS. Technical Report, MRC Biostatistics Unit, University of Cambridge, 1999.
17. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPVpositive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013;14(2):168-176.
18. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer. 2005;93(8):862-867.
19. Benoy IH, Vanden Broek D, Ruymbeke MJ, et al. Prior knowledge of HPV stats improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol. 2011;205(6):569.e1-e7.
20. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9): 880-890.
21. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. New Engl J Med. 2007;357(16):1579-1588.
22. Zorzi M, Del Mistro A, Farruggio A, et al. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study. BJOG. 2013;120(10):1260-1267.
23. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid-based versus conventional cytology: overall results of the new technologies for cervical cancer screening randomised controlled trial. BMJ. 2007;335(7609):28-31.
24. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009;302(16):1757-1764.
25. Confortini M, Bergeron C, Desai M, et al. Accuracy of liquid based cytology: comparison of the results obtained within a randomized controlled trial (NTCC) and an external group of experts. Cancer Cytopathol. 2010;118(4):203-208.
26. Rodríguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315-324.